Atomera Incorporated vs Revvity Inc — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while Revvity Inc trades at $115.76 (market cap $12.94B). The key difference: Revvity Inc is far larger — about 61.7× Atomera Incorporated's market cap, and Revvity Inc pays a 0.24% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ATOM | RVTY | |
|---|---|---|
Market Cap | $209.56M | $12.94B |
Sector | Technology | Technology |
52-Week High | $12.11 | $117.75 |
52-Week Low | $1.99 | $82.26 |
Enterprise Value | $172.37M | $15.26B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
RVTY trades at $114.66, up 0.37% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 54.98% gross margin and $241.20M net income for 2025, supported by positive news including product launches and raised 2026 guidance. Analyst consensus is a buy with a $120.50 price target, indicating potential upside from current levels.
Outlook remains positive due to consistent earnings outperformance and innovation in diagnostics, but risks include high P/E valuation and competitive pressures. Investors may find opportunity in sustained margin strength and AI integration, though macroeconomic sensitivity warrants caution.
Trailing returns across standard periods
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →